Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein...
Gespeichert in:
| Veröffentlicht in: | Cancers 2020-08, Vol.12 (8), p.2299 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2299 |
| container_title | Cancers |
| container_volume | 12 |
| creator | Wakasaki, Takahiro Yasumatsu, Ryuji Masuda, Muneyuki Takeuchi, Toranoshin Manako, Tomomi Matsuo, Mioko Jiromaru, Rina Uchi, Ryutaro Komune, Noritaka Noda, Teppei Nakagawa, Takashi |
| description | Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP ( |
| doi_str_mv | 10.3390/cancers12082299 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7463840</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639969577</galeid><sourcerecordid>A639969577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-4d01d38d5cea8003337c8c4ba70aa4fd2888c160286a04c5cae79f1878b5a1c43</originalsourceid><addsrcrecordid>eNpdkk9v3CAQxa2qVROlOfeK1Esv28WAAV8qpVbTVErTqknPaBaPvSQ2bMDeKh8j3zhYifonXIDh6TfvoSmKtyX9wHlN1xa8xZhKRjVjdf2iOGRUsZWUtXj5z_mgOE7pmubFeamkel0ccKaZYEweFvc_Yuh9SJOz5JMLI8SbjCShI5cw7KFH0mxxDNMWI-zuyGkYhvDb-Z5cuH0Y5hE25CoiTCP6iXQhkp9o5xiXG_h2nQvfcII0wdLgDKFdyuQC7Q25vJ1hDHMiDQ4DaSBa57OBN8WrDoaEx0_7UfHr9PNVc7Y6__7la3NyvrKiZtNKtLRsuW4ri6CXaFxZbcUGFAUQXcu01raUlGkJVNjKAqq6K7XSmwpKK_hR8fGRu5s3I7Y2W44wmF10-RPuTABn_n_xbmv6sDdKSK4FzYD3T4AYbmdMkxldsjkLeMyxDBNcCkqlVln67pn0OszR53iLqsouuZJ_VT0MaJzvQu5rF6g5kbyuZV2phbV-VNkYUorY_bFcUrPMhXk2F_wBMmOsyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435602376</pqid></control><display><type>article</type><title>Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Wakasaki, Takahiro ; Yasumatsu, Ryuji ; Masuda, Muneyuki ; Takeuchi, Toranoshin ; Manako, Tomomi ; Matsuo, Mioko ; Jiromaru, Rina ; Uchi, Ryutaro ; Komune, Noritaka ; Noda, Teppei ; Nakagawa, Takashi</creator><creatorcontrib>Wakasaki, Takahiro ; Yasumatsu, Ryuji ; Masuda, Muneyuki ; Takeuchi, Toranoshin ; Manako, Tomomi ; Matsuo, Mioko ; Jiromaru, Rina ; Uchi, Ryutaro ; Komune, Noritaka ; Noda, Teppei ; Nakagawa, Takashi</creatorcontrib><description>Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12082299</identifier><identifier>PMID: 32824226</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biomarkers ; C-reactive protein ; Cancer ; Cancer therapies ; Chemotherapy ; Disease control ; Drug therapy ; Head & neck cancer ; Head and neck cancer ; Immune checkpoint inhibitors ; Immunotherapy ; Lymphocytes ; Medical prognosis ; Metastases ; Metastasis ; Monoclonal antibodies ; Multivariate analysis ; Paclitaxel ; Patient outcomes ; Pneumonia ; Prognosis ; Skin diseases ; Squamous cell carcinoma ; Targeted cancer therapy ; Tegafur ; Tumors</subject><ispartof>Cancers, 2020-08, Vol.12 (8), p.2299</ispartof><rights>COPYRIGHT 2020 MDPI AG</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-4d01d38d5cea8003337c8c4ba70aa4fd2888c160286a04c5cae79f1878b5a1c43</citedby><cites>FETCH-LOGICAL-c492t-4d01d38d5cea8003337c8c4ba70aa4fd2888c160286a04c5cae79f1878b5a1c43</cites><orcidid>0000-0001-7736-9162 ; 0000-0001-6199-0341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463840/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463840/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Masuda, Muneyuki</creatorcontrib><creatorcontrib>Takeuchi, Toranoshin</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Jiromaru, Rina</creatorcontrib><creatorcontrib>Uchi, Ryutaro</creatorcontrib><creatorcontrib>Komune, Noritaka</creatorcontrib><creatorcontrib>Noda, Teppei</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><title>Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma</title><title>Cancers</title><description>Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.</description><subject>Biomarkers</subject><subject>C-reactive protein</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Disease control</subject><subject>Drug therapy</subject><subject>Head & neck cancer</subject><subject>Head and neck cancer</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Multivariate analysis</subject><subject>Paclitaxel</subject><subject>Patient outcomes</subject><subject>Pneumonia</subject><subject>Prognosis</subject><subject>Skin diseases</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><subject>Tegafur</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkk9v3CAQxa2qVROlOfeK1Esv28WAAV8qpVbTVErTqknPaBaPvSQ2bMDeKh8j3zhYifonXIDh6TfvoSmKtyX9wHlN1xa8xZhKRjVjdf2iOGRUsZWUtXj5z_mgOE7pmubFeamkel0ccKaZYEweFvc_Yuh9SJOz5JMLI8SbjCShI5cw7KFH0mxxDNMWI-zuyGkYhvDb-Z5cuH0Y5hE25CoiTCP6iXQhkp9o5xiXG_h2nQvfcII0wdLgDKFdyuQC7Q25vJ1hDHMiDQ4DaSBa57OBN8WrDoaEx0_7UfHr9PNVc7Y6__7la3NyvrKiZtNKtLRsuW4ri6CXaFxZbcUGFAUQXcu01raUlGkJVNjKAqq6K7XSmwpKK_hR8fGRu5s3I7Y2W44wmF10-RPuTABn_n_xbmv6sDdKSK4FzYD3T4AYbmdMkxldsjkLeMyxDBNcCkqlVln67pn0OszR53iLqsouuZJ_VT0MaJzvQu5rF6g5kbyuZV2phbV-VNkYUorY_bFcUrPMhXk2F_wBMmOsyQ</recordid><startdate>20200815</startdate><enddate>20200815</enddate><creator>Wakasaki, Takahiro</creator><creator>Yasumatsu, Ryuji</creator><creator>Masuda, Muneyuki</creator><creator>Takeuchi, Toranoshin</creator><creator>Manako, Tomomi</creator><creator>Matsuo, Mioko</creator><creator>Jiromaru, Rina</creator><creator>Uchi, Ryutaro</creator><creator>Komune, Noritaka</creator><creator>Noda, Teppei</creator><creator>Nakagawa, Takashi</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7736-9162</orcidid><orcidid>https://orcid.org/0000-0001-6199-0341</orcidid></search><sort><creationdate>20200815</creationdate><title>Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma</title><author>Wakasaki, Takahiro ; Yasumatsu, Ryuji ; Masuda, Muneyuki ; Takeuchi, Toranoshin ; Manako, Tomomi ; Matsuo, Mioko ; Jiromaru, Rina ; Uchi, Ryutaro ; Komune, Noritaka ; Noda, Teppei ; Nakagawa, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-4d01d38d5cea8003337c8c4ba70aa4fd2888c160286a04c5cae79f1878b5a1c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers</topic><topic>C-reactive protein</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Disease control</topic><topic>Drug therapy</topic><topic>Head & neck cancer</topic><topic>Head and neck cancer</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Multivariate analysis</topic><topic>Paclitaxel</topic><topic>Patient outcomes</topic><topic>Pneumonia</topic><topic>Prognosis</topic><topic>Skin diseases</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><topic>Tegafur</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Masuda, Muneyuki</creatorcontrib><creatorcontrib>Takeuchi, Toranoshin</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Jiromaru, Rina</creatorcontrib><creatorcontrib>Uchi, Ryutaro</creatorcontrib><creatorcontrib>Komune, Noritaka</creatorcontrib><creatorcontrib>Noda, Teppei</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wakasaki, Takahiro</au><au>Yasumatsu, Ryuji</au><au>Masuda, Muneyuki</au><au>Takeuchi, Toranoshin</au><au>Manako, Tomomi</au><au>Matsuo, Mioko</au><au>Jiromaru, Rina</au><au>Uchi, Ryutaro</au><au>Komune, Noritaka</au><au>Noda, Teppei</au><au>Nakagawa, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma</atitle><jtitle>Cancers</jtitle><date>2020-08-15</date><risdate>2020</risdate><volume>12</volume><issue>8</issue><spage>2299</spage><pages>2299-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32824226</pmid><doi>10.3390/cancers12082299</doi><orcidid>https://orcid.org/0000-0001-7736-9162</orcidid><orcidid>https://orcid.org/0000-0001-6199-0341</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2020-08, Vol.12 (8), p.2299 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7463840 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Biomarkers C-reactive protein Cancer Cancer therapies Chemotherapy Disease control Drug therapy Head & neck cancer Head and neck cancer Immune checkpoint inhibitors Immunotherapy Lymphocytes Medical prognosis Metastases Metastasis Monoclonal antibodies Multivariate analysis Paclitaxel Patient outcomes Pneumonia Prognosis Skin diseases Squamous cell carcinoma Targeted cancer therapy Tegafur Tumors |
| title | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T09%3A17%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Biomarkers%20of%20Salvage%20Chemotherapy%20Following%20Nivolumab%20Treatment%20for%20Recurrent%20and/or%20Metastatic%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma&rft.jtitle=Cancers&rft.au=Wakasaki,%20Takahiro&rft.date=2020-08-15&rft.volume=12&rft.issue=8&rft.spage=2299&rft.pages=2299-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12082299&rft_dat=%3Cgale_pubme%3EA639969577%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435602376&rft_id=info:pmid/32824226&rft_galeid=A639969577&rfr_iscdi=true |